{"id":197991,"name":"ORGANOGENESIS INC.","slug":"organogenesis-inc","state":"MA","country":"United States of America","description":"","totalSpending":3983000,"filings":30,"yearlySpending":[{"year":2019,"income":210000},{"year":2020,"income":260000},{"year":2021,"income":210000},{"year":2022,"income":360000},{"year":2023,"income":840000},{"year":2024,"income":1013000},{"year":2025,"income":1090000}],"issues":[{"code":"DEF","display":"Defense"},{"code":"MMM","display":"Medicare/Medicaid"},{"code":"VET","display":"Veterans"},{"code":"TAX","display":"Taxation/Internal Revenue Code"},{"code":"HCR","display":"Health Issues"},{"code":"MAN","display":"Manufacturing"}],"firms":["ORGANOGENESIS INC."],"lobbyists":["ARTHUR-PAUL PETROSINELLI"],"govEntities":["HOUSE OF REPRESENTATIVES","SENATE","Centers For Medicare and Medicaid Services (CMS)","Executive Office of the President (EOP)","Office of Management & Budget (OMB)"],"sampleDescriptions":["Medicare reimbursement policy including hospital outpatient prospective payment system (HOPPS) rule; Medical device tax repeal; Food and Drug Administration policy on regenerative medicine and chronic","Medicare reimbursement policy including hospital outpatient prospective payment system (HOPPS) rule; Medical device tax repeal; Food and Drug Administration policy on regenerative medicine and chronic","Medicare reimbursement policy including hospital outpatient prospective payment system (HOPPS) rule; Medical device tax repeal; Food and Drug Administration policy on regenerative medicine and chronic","Medicare reimbursement policy including hospital outpatient prospective payment system (HOPPS) rule; Medical device tax repeal; Food and Drug Administration policy on regenerative medicine and chronic","Medicare reimbursement policy including hospital outpatient prospective payment system (HOPPS) rule; Medical device tax repeal; Food and Drug Administration policy on regenerative medicine and chronic"]}